-+ 0.00%
-+ 0.00%
-+ 0.00%

Opus Genetics' OPGx-BEST1 improves retinal sensitivity in 75% of evaluable patients in early-stage trial

PUBT·10/15/2026 20:00:37
Listen to the news
Opus Genetics' OPGx-BEST1 improves retinal sensitivity in 75% of evaluable patients in early-stage trial
  • Opus Genetics presented positive clinical results for its OPGx-LCA5 and OPGx-BEST1 gene therapies at Retina in Rio 2026.
  • OPGx-LCA5 showed sustained vision improvements in adults through 24 months, with encouraging pediatric results through six months.
  • The fully enrolled OPGx-LCA5 Phase 3 trial is expected to begin dosing in the fourth quarter of 2026.
  • OPGx-BEST1 improved retinal sensitivity in most evaluable low-dose participants, supporting further development.
  • The OPGx-BEST1 Phase 1/2 trial completed high-dose cohort enrollment with 11 participants.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opus Genetics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610151600PRIMZONEFULLFEED9846869) on October 15, 2026, and is solely responsible for the information contained therein.